-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On August 9th, Anke Biological issued an announcement stating that its shareholding company, Boshengji, received the "Drug Clinical Trial Approval Notice" approved and issued by the National Medical Products Administration, agreeing to carry out the treatment of adult relapsed/refractory CD7 positive blood Clinical trials for malignant tumors of the lymphatic system
This clinical trial approval is the first international nanobody-based CD7-CAR-T cell injection (development code: PA3-17 injection) independently developed by Boshengji Company.
Most of the CD7-positive malignant tumors are highly aggressive lymphomas or leukemias.